HitGen Past Earnings Performance
Past criteria checks 3/6
HitGen's earnings have been declining at an average annual rate of -21.8%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been growing at an average rate of 9.1% per year. HitGen's return on equity is 3.2%, and it has net margins of 11%.
Key information
-21.8%
Earnings growth rate
-23.9%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 9.1% |
| Return on equity | 3.2% |
| Net Margin | 11.0% |
| Next Earnings Update | 26 Oct 2024 |
Recent past performance updates
Recent updates
Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking
Oct 08
HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate
Jul 03HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly
Jun 06HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors
Mar 07Revenue & Expenses Breakdown
How HitGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 410 | 45 | 94 | 71 |
| 31 Mar 24 | 409 | 64 | 93 | 72 |
| 31 Dec 23 | 371 | 41 | 94 | 79 |
| 30 Sep 23 | 357 | 33 | 91 | 82 |
| 30 Jun 23 | 347 | 38 | 92 | 84 |
| 31 Mar 23 | 327 | 23 | 89 | 91 |
| 31 Dec 22 | 330 | 25 | 92 | 87 |
| 30 Sep 22 | 302 | 44 | 88 | 86 |
| 30 Jun 22 | 296 | 36 | 85 | 83 |
| 31 Mar 22 | 314 | 51 | 84 | 76 |
| 31 Dec 21 | 311 | 63 | 77 | 74 |
| 30 Sep 21 | 345 | 79 | 80 | 75 |
| 30 Jun 21 | 311 | 69 | 69 | 87 |
| 31 Mar 21 | 269 | 61 | 61 | 90 |
| 31 Dec 20 | 244 | 64 | 52 | 98 |
| 30 Sep 20 | 235 | 61 | 53 | 104 |
| 30 Jun 20 | 244 | 76 | 53 | 97 |
| 31 Mar 20 | 258 | 85 | 59 | 91 |
| 31 Dec 19 | 264 | 120 | 59 | 87 |
| 31 Dec 18 | 151 | 45 | 37 | 58 |
| 31 Dec 17 | 53 | -23 | 31 | 45 |
Quality Earnings: 688222 has high quality earnings.
Growing Profit Margin: 688222's current net profit margins (11%) are lower than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688222's earnings have declined by 21.8% per year over the past 5 years.
Accelerating Growth: 688222's earnings growth over the past year (18.2%) exceeds its 5-year average (-21.8% per year).
Earnings vs Industry: 688222 earnings growth over the past year (18.2%) exceeded the Life Sciences industry -7.5%.
Return on Equity
High ROE: 688222's Return on Equity (3.2%) is considered low.